by Madaline Spencer | Dec 1, 2025
Nolan Campbell, PhD, U.S. Medical Director at Johnson & Johnson, discusses the EPIC clinical trial design that will evaluate the efficacy of nipocalimab versus efgartigimod in patients with generalized myasthenia gravis (gMG). gMG is a chronic...
by Madaline Spencer | Nov 26, 2025
Sindhu Ramchandren, MD, Executive Medical Director of Neuroscience at Johnson & Johnson, discusses long-term efficacy of nipocalimab in patients with generalized myasthenia gravis (gMG). gMG is a chronic autoimmune neuromuscular disease characterized...
by Madaline Spencer | Nov 25, 2025
The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib was first approved in 2020 for pediatric...
by Madaline Spencer | Nov 24, 2025
The U.S. Food and Drug Administration (FDA) has updated the prescribing information for Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy (DMD). DMD is a rare genetic, neuromuscular condition characterized by progressive muscle wasting. Symptoms...
by Madaline Spencer | Nov 21, 2025
The U.S. Food and Drug Administration (FDA) has approved Redemplo (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome (FCS). FCS is an inherited condition that disrupts the normal breakdown of fats in the body, causing large amounts...
